NewLink nets $20M Ebola milestone from Merck

NewLink's ($NLNK) Ebola vaccine tie-up with Merck ($MRK) continues to pay off. The Iowa-based company has triggered a milestone payment from the pharma giant worth $20 million, it said last week, and it'll put the money back into its vaccine work for infectious diseases. Release

Suggested Articles

GSK isn't alone in facing a slowdown amid the COVID-19 pandemic, but its big vaccines presence makes 2020 particularly tough for the British pharma.

Experts are divided on whether the U.S. should hold out for an optimal COVID vaccine or accept the best shot it can muster within the next few months.

Sanofi and GSK have agreed to provide 200 million doses of their vaccine to COVAX, a global effort to develop, produce and equitably distribute doses.